The estimated Net Worth of Diana Brainard is at least $1.25 Million dollars as of 20 August 2024. Dr Brainard owns over 5,390 units of AlloVir stock worth over $572,981 and over the last 4 years he sold ALVR stock worth over $653,502. In addition, he makes $20,000 as CEO & Director at AlloVir.
Sign up
Dr D ALVR stock SEC Form 4 insiders trading
Dr has made over 28 trades of the AlloVir stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 5,390 units of ALVR stock worth $3,989 on 20 August 2024.
The largest trade he's ever made was selling 41,421 units of AlloVir stock on 5 February 2024 worth over $27,752. On average, Dr trades about 7,334 units every 41 days since 2020. As of 20 August 2024 he still owns at least 753,923 units of AlloVir stock.
You can see the complete history of Dr Brainard stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Diana M. Brainard M.D. biography
Dr. Diana M. Brainard M.D. is the CEO & Director at AlloVir.
What is the salary of Dr D?
As the CEO & Director of AlloVir, the total compensation of Dr D at AlloVir is $20,000. There are 4 executives at AlloVir getting paid more, with David L. Hallal having the highest compensation of $981,018.
How old is Dr D?
Dr D is 50, he's been the CEO & Director of AlloVir since . There are 7 older and 2 younger executives at AlloVir. The oldest executive at AlloVir, Inc. is Vikas Sinha C.A., CPA, M.B.A., 58, who is the Pres, CFO & Director.
What's Dr D's mailing address?
Diana's mailing address filed with the SEC is C/O ALLOVIR, INC., P.O. BOX 44, 1661 MASSACHUSETTS AVE., LEXINGTON, MA, 02420.
Insiders trading at AlloVir
Over the last 4 years, insiders at AlloVir have traded over $46,310,999 worth of AlloVir stock and bought 5,850,170 units worth $60,516,413 . The most active insiders traders include Sciences, Inc. Gilead, Group, Llc Green Jeremy Red... und Ansbert Gadicke. On average, AlloVir executives and independent directors trade stock every 9 days with the average trade being worth of $40,307. The most recent stock trade was executed by Diana Brainard on 20 August 2024, trading 5,390 units of ALVR stock currently worth $3,989.
What does AlloVir do?
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
What does AlloVir's logo look like?
Complete history of Dr Brainard stock trades at Nektar Therapeutics und AlloVir
AlloVir executives and stock owners
AlloVir executives and other stock owners filed with the SEC include:
-
David L. Hallal,
Exec. Chairman -
Vikas Sinha C.A., CPA, M.B.A.,
Pres, CFO & Director -
Vikas Sinha,
Pres, CFO & Director -
Dr. Ercem Atillasoy M.D.,
Chief Regulatory & Safety Officer -
Dr. Diana M. Brainard M.D.,
CEO & Director -
Sonia Choi,
Sr. VP of Corp. Affairs & Investor Relations -
Ugo Capolino Perlingieri,
Head & GM of Europe and Middle East Operations -
Dr. Jeroen Van Beek Ph.D.,
Chief Commercial Officer -
Edward Miller,
Gen. Counsel & Sec. -
Medha Chadha M.B.A.,
Sr. VP of Strategic Planning & Investor Relations -
Dr. Ann M. Leen Ph.D.,
Chief Scientific Officer -
Brett R. Hagen,
Chief Accounting Officer -
Agustin Melian M.D.,
Advisor -
Sciences, Inc. Gilead,
10% owner -
Edward Miller,
General Counsel -
Diana Brainard,
Chief Executive Officer -
Llc Elevate Bio,,
Director -
Juan Vera,
-
Group, Llc Green Jeremy Red...,
-
Ann M. Leen,
Chief Scientific Officer -
John Robert Wilson,
Director -
Ercem Atillasoy,
See Remarks -
Beek Jeroen B Van,
Chief Commercial Officer -
Agustin Melian,
Chief Medical Officer -
Brett R Hagen,
Chief Accounting Officer -
Ansbert Gadicke,
Director -
Morana Jovan Embiricos,
-
Vikas Sinha,
See Remarks -
Cintia Piccina,
Chief Commercial Officer -
Shawn Tomasello,
-
Malcolm Brenner,
-
David Hallal,
-
Jeffrey S Bornstein,